In conjunction with potential spin out of the diagnostics division, we are likely to hear developments in regard to Lympro CTE/TBI, BC-SeraPro, and NuroPro. These assets have not been mentioned in some time now, but will likely be addressed prior to, or along with, spin out talk. If a large diagnostics company wanted to take a major stake in the stand-alone diagnostics company they would have to value all these assets including Lympro for Alzheimer's. I also would not be surprised if they acquired another diagnostic asset prior to spin out to bolster the portfolio of the diagnostic company. AMBS certainly could launch Lympro on their own in RUO market and then use the profits to launch commercially under CLIA etc. However, they don't have the resources to exploit the other diagnostic assets quickly. A large diagnostics company can do that. A major diagnostics partner could develop and commercialize these assets under the new diagnostics company and AMBS could receive a large upfront payment and then collect share of profit. AMBS could then focus on Eltoprazine, ESS, and MANF under the Therapeutics division and just collect a routine check from the diagnostics division until an outright sale of the division is agreed upon.